First and only drug releasing system to provide extended local delivery of a cancer medication into the bladder, with 82 percent of patients achieving complete response without the need for ...
IL-15RαFc superagonist SHR-1501 with or without bacille Calmette Guerin (BCG) for high-risk non-muscle invasive bladder cancer (NMIBC): A phase 1/2 study. RFS rate in all Pts, % ( 95%CI) 96 (88, 100) ...
ScRNA-seq profiles to identify HES1 associated with ACTH-secreting tumors and the distinct microenvironment between ACTH+/CRH+ and ACTH-/CRH- pheochromocytomas. This is an ASCO Meeting Abstract from ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
New data from Cohort 4 of the SunRISe-1 study show more than 95 percent of patients remained progression free at one year, with more than 92 percent not undergoing bladder removal Patients with this ...
Zusduri is expected to be available on or around July 1, 2025. The Food and Drug Administration (FDA) has approved Zusduri (mitomycin intravesical solution) for adults with recurrent low-grade ...
Immvira Group Co.’s oncolytic herpes simplex virus product, MVR-T3011, showed early efficacy via intravesical administration in patients with high-risk BCG-failure non-muscle invasive bladder cancer.
SHENZHEN, China, Sept. 15, 2024 /PRNewswire/ -- ImmVira announced the latest clinical results for its lead oncolytic virus product, MVR-T3011, via intravesical administration in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results